Masimo extends strategic partnership with Philips through 2026

Masimo (NASDAQ: MASI) announced a multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG, AEX: PHIA), extending their collaboration through 2026 and beyond.

The expanded partnership will accelerate integration of Masimo's monitoring technologies into Philips multi-parameter patient monitors. This includes incorporating Masimo's SET pulse oximetry and Radius PPG technology with Masimo-board equipped Philips monitors and next-generation wearable solutions.

The companies will integrate Masimo sensor technology with all Masimo-equipped Philips bedside monitors and central stations. They plan to jointly develop, produce, and co-promote artificial intelligence-based monitoring technologies.

Several Masimo monitoring technologies are already available on Philips devices, including continuous hemoglobin (SpHb), O3 regional oximetry, SedLine brain function monitoring, and NomoLine capnography. Philips will expedite adoption of these technologies in additional devices and market segments.

"We are excited to continue to partner with Philips to bring Masimo's newest innovations in wearables and artificial intelligence to Philips' platforms," said Katie Szyman, CEO of Masimo.

Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips, said the partnership allows the companies to respond to clinical needs and market trends by integrating technologies into scalable solutions.

The partnership builds on over two decades of collaboration between the medical technology companies, according to the press release.

You May Also Be Interested In

• QXO prices $3 billion in senior notes to fund TopBuild acquisition
• Aeva Technologies files mixed shelf offering registration
• 3D Systems announces $40 million public stock offering